Annual report pursuant to Section 13 and 15(d)

Income Taxes

v3.19.3.a.u2
Income Taxes
12 Months Ended
Dec. 31, 2019
Income Taxes  
Income Taxes

10. Income Taxes

The components of loss before income taxes are as follows:

 

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2019

    

2018

Domestic

 

$

(7,523,695)

 

$

(11,242,646)

Foreign

 

 

522,395

 

 

517,268

Total Loss Before Income Taxes

 

$

(7,001,300)

 

$

(10,725,378)

 

The components of income tax expense are as follows:

 

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2019

    

2018

Deferred Taxes:

 

 

  

 

 

  

Federal

 

$

(4,182)

 

$

1,814

State

 

 

99,578

 

 

84,231

Total Deferred Taxes

 

$

95,396

 

$

86,045

Income Tax Expense

 

$

95,396

 

$

86,045

 

The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

 

    

2019

    

2018

 

United States Federal Income Tax Rate

 

21.00

%  

21.00

%

State Taxes, Net of Federal Benefit

 

13.82

 

(0.38)

 

Permanent Differences

 

(4.18)

 

(1.48)

 

Change in Valuation Allowance

 

(37.40)

 

3.88

 

Research and Development Credits

 

6.53

 

1.06

 

Tax Rate Differential

 

(1.15)

 

(1.33)

 

Topic 606 Adoption

 

 —

 

(20.90)

 

Stock-Based Compensation

 

0.45

 

0.00

 

Other

 

(0.43)

 

(2.65)

 

Effective Tax Rate Expense

 

(1.36)

%  

(0.80)

%

 

The Company’s deferred tax assets and liabilities consist of the following:

 

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2019

    

2018

Net Deferred Tax Liability:

 

 

 

 

 

 

Net Operating Loss Carryforwards

 

$

15,230,646

 

$

13,601,705

Research and Development Credit Carryforwards

 

 

2,594,055

 

 

2,124,949

Capitalized Research and Development

 

 

6,521,705

 

 

5,861,675

Stock-Based Compensation

 

 

814,438

 

 

639,729

Depreciation and Amortization

 

 

170

 

 

(3,217)

Cash Versus Accrual Adjustments

 

 

1,738,482

 

 

2,069,985

Total Deferred Tax Assets

 

 

26,899,496

 

 

24,294,826

Valuation Allowance

 

 

(26,278,147)

 

 

(23,659,844)

Net Deferred Tax Asset

 

 

621,349

 

 

634,982

In-Process Research and Development

 

 

(986,713)

 

 

(904,950)

Net Deferred Tax Liability

 

$

(365,364)

 

$

(269,968)

 

As of December 31, 2019, the Company has federal and state net operating loss carryforwards of approximately $59,013,000 and $41,088,000, respectively, to offset future federal and state taxable income. Federal NOL carryforwards as of December 31, 2017 totaling $46.055 million and state NOL carryforwards as of December 31, 2019 totaling $41.088 million will expire at various times through 2039. Federal NOL carryforwards generated during the years ended December 31, 2019 and 2018 totaling $12.958 million  will carry forward indefinitely, but their utilization will be limited to 80% of taxable income. The Company has foreign net operating loss carryforwards of $1,565,000 as of December 31, 2019, which can be carried forward indefinitely. As of December 31, 2019, the Company also has federal, state and foreign research and development tax credit carryforwards of approximately $2,171,000,  $504,000, and $25,000, respectively, to offset future income taxes, which expire at various times through 2039. The federal and state net operating loss and research tax credit carryforwards may be subject to the limitations provided in the Internal Revenue Code (“IRC”) Sections 382 and 383. Approximately $638,000 of the federal net operating loss attributable to Jade is subject to a Section 382 limitation. Jade’s carryover of its research and development credits will be subject to the Section 383 limitation.

The Company files United States federal income tax returns and income tax returns in the Commonwealth of Massachusetts, Utah, and New Jersey, as well as foreign tax returns for its subsidiary in France. The Company is not under examination by any jurisdiction for any tax year.

The Company has recorded a valuation allowance against its United States deferred tax assets in each of the years ended December 31, 2019, and 2018 because the Company’s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased (decreased) by approximately $2,618,000 and ($416,000) during the years ended December 31, 2019 and 2018, respectively, primarily as a result of adjustments for accrual to cash basis items, the adoption of Topic 606, capitalized research and development expenses, and a reduction in the U.S. federal tax rate.

Effective January 1, 2019, the Company adopted ASU 2016-02, which resulted in recognition of lease liabilities and right-of-use assets. The adoption did not have material impact on the deferred tax balances as of December 31, 2019.

As of December 31, 2019 and 2018, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company will recognize interest and penalties related to tax positions in income tax expense. The Company has not, as yet, conducted a study of R&D credit carryforwards, which are fully reserved for. This study may result in an adjustment to the Company’s R&D credit carryforwards and related valuation allowance, however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position.

The net operating loss and tax credit carryforwards are subject to review by the Internal Revenue Service in accordance with the provisions of Section 382 of the Internal Revenue Code. Under this Internal Revenue Code section, substantial changes in the Company’s ownership may limit the amount of net operating loss carryforwards that could be utilized annually in the future to offset the Company’s taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. Any such annual limitation may significantly reduce the utilization of the Company’s net operating loss carryforwards before they expire. The closing of the Company’s initial public offering, alone or together with transactions that have occurred or that may occur in the future, may trigger an ownership change pursuant to Section 382, which could limit the amount of research and development tax credit and net operating loss carryforwards that could be utilized annually in the future to offset the Company’s taxable income, if any. Any such limitation as the result of the Company’s additional sales of common stock by the Company could have a material adverse effect on the Company’s results of operations in future years.